Insight on Pharmaceuticals and Healthcare in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

The Contract Biomanufacturing Market Outlook to 2017

The biologic drug market is growing at nearly twice the pace of the overall pharma market. This report forecasts microbial and mammalian contract manufacturing markets to 2017. Market dynamics and leading players are also examined.

Published By Datamonitor
19 Feb 2013 $2800
Buy
Case Studies
Case Studies

The "Patent Cliff": How Pfizer has responded to the loss of its best-selling drug

The pharmaceuticals market is currently in the middle of a "patent cliff." This case study looks at the various routes companies are taking in order to minimize the adverse effects caused by the patent cliff.

Published By MarketLine
08 Jun 2012 $495
Buy
Report
Report

Strategies for Comparative Efficacy Trials

Comparative efficacy data are not necessarily required for approval but are increasingly demanded by payers. Meeting the expectations of all stakeholders can be challenging, making comparator selection and trial design complex decisions.

Published By Datamonitor
23 Aug 2012 $2800
Buy
Report
Report

Strategies and Technologies for Target Validation

High Phase II attrition is hampering the pharma industry’s ability to reach sustainable rates of innovation. More rigorous validation of new biological targets prior to clinical development is essential for increasing R&D efficiency.

Published By Datamonitor
28 Sep 2012 $2800
Buy
Report
Report

Stakeholder Opinions: Tropical Diseases - Dengue, Japanese encephalitis and West Nile virus – Increasing attention for neglected diseases

This report explores key issues in dengue, Japanese encephalitis and West Nile infection. It contains an analysis of epidemiological trends, assessment of marketed vaccines and discusses the pipeline for vaccines and virus-specific therapeutics.

Published By Datamonitor
14 Dec 2010 $2800
Buy

Order this report by October 22nd 2010 and receive a 30% discount

To take advantage of this offer enter Promo Code TBI30 when prompted in the checkout

More information

Report
Report

Stakeholder Opinions: Traumatic Brain Injury - Hormonal therapy generates optimism

Analysis of traumatic brain injury epidemiology, unmet needs and pipeline treatments. Provides analysis of opportunities and threats facing developers of TBI treatments based on interviews with six key opinion leaders.

Published By Datamonitor
07 Apr 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatness

This report assesses the current landscape of and future opportunities for therapeutic vaccines outside cancer, covering therapeutic vaccine approaches in cardiovascular and metabolic, CNS, autoimmune and infectious diseases.

Published By Datamonitor
17 Dec 2009 $3800
Buy
Report
Report

Stakeholder Opinions: Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market

Assessment of the potential impact of agents targeting nerve growth factor (NGF) for the treatment of pain. Includes analysis of the key market drivers and resistors for this new class based on interviews with key opinion leaders.

Published By Datamonitor
05 Mar 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential

Analysis of spinal cord injury epidemiology, unmet needs and pipeline treatments. Provides assessment of potential market value and analysis of opportunities and threats facing developers of SCI treatments based on interviews with key opinion leaders

Published By Datamonitor
05 Mar 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Skin and Soft Tissue Infections - The end of the reign of vancomycin

This report gives a comprehensive overview of trends in epidemiology, diagnosis, treatment and referral patterns for skin and soft tissue infections (SSTIs). It discusses the challenges, opportunities and future developments for the SSTI drug market.

Published By Datamonitor
16 Jul 2009 $3800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.